Updating results

144 results for Hepatitis C

Sort: Relevance | Date

Glecaprevir–pibrentasvir for treating chronic hepatitis C (TA499)

Evidence-based recommendations on glecaprevir–pibrentasvir (Maviret) for treating chronic hepatitis C in adults

Technology appraisal guidance Published January 2018

Sofosbuvir–velpatasvir for treating chronic hepatitis C (TA430)

Evidence-based recommendations on sofosbuvir–velpatasvir (Epclusa) for treating chronic hepatitis C in adults

Technology appraisal guidance Published January 2017

Sofosbuvir for treating chronic hepatitis C (TA330)

Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)

Technology appraisal guidance Published February 2015

Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C (TA507)

Evidence-based recommendations on sofosbuvir–velpatasvir–voxilaprevir (Vosevi) for treating chronic hepatitis C (HCV) in adults

Technology appraisal guidance Published February 2018

Ledipasvir–sofosbuvir for treating chronic hepatitis C (TA363)

Evidence-based recommendations on ledipasvir–sofosbuvir (Harvoni) for treating some types (genotypes) of chronic hepatitis C

Technology appraisal guidance Published November 2015

Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C (TA106)

Evidence-based recommendations on peginterferon alfa (Pegasys) and ribavirin (Copegus) for treating mild chronic hepatitis C

Technology appraisal guidance Published August 2006 Last updated November 2013

Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C (TA200)

Evidence-based recommendations on peginterferon alfa (2a [Pegasys] or 2b [ViraferonPeg]) and ribavirin (Copegus or Rebetol) for treating chronic hepatitis C

Technology appraisal guidance Published September 2010

Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C (TA365)

Evidence-based recommendations on ombitasvir–paritaprevir–ritonavir (Viekirax) with or without dasabuvir (Exviera) for some types of chronic hepatitis C

Technology appraisal guidance Published November 2015

Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C (TA75)

Evidence-based recommendations on interferon alfa (pegylated and non-pegylated) and ribavirin for treating chronic hepatitis C

Technology appraisal guidance Published January 2004 Last updated November 2013

Hepatitis B and C testing: people at risk of infection (PH43)

This guideline covers raising awareness of and testing for hepatitis B and C infection. It aims to ensure that people at increased risk of hepatitis B and C infection are tested.

Public health guideline Published December 2012 Last updated March 2013

Hepatitis B and C testing

Hepatitis B and C: ways to promote and offer testing to people at increased risk of infection.

NICE Pathway Published December 2012 Last updated August 2017

The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)

Advice on the use of the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies to aid local decision-making

Medtech innovation briefing Published March 2015

Liver conditions

Everything NICE has said on liver conditions in an interactive flowchart

NICE Pathway Published March 2014 Last updated February 2019

Needle and syringe programmes (PH52)

This guideline covers needle and syringe programmes for people (including those under 16) who inject drugs. The main aim is to reduce the transmission of viruses and other infections caused by sharing injecting equipment, such as HIV, hepatitis B and C. In turn, this will reduce the prevalence of blood-borne viruses and bacterial infections, so benefiting wider society.

Public health guideline Published March 2014

Virtual Touch Quantification to diagnose and monitor liver fibrosis in chronic hepatitis B and C (MTG27)

Evidence-based recommendations on Virtual Touch Quantification for diagnosing and monitoring liver fibrosis in chronic Hepatitis B and C

Medical technologies guidance Published September 2015

Cirrhosis in over 16s: assessment and management (NG50)

This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed. It recommends tools to assess the severity of cirrhosis and gives advice on monitoring people with cirrhosis to detect and manage complications early, and referral criteria for tertiary care.

NICE guideline Published July 2016

Drug use disorders in adults (QS23)

This quality standard covers assessment and treatment of drug use disorders in adults (aged 18 and over). It includes treating the misuse of opioids, cannabis, stimulants and other drugs in all settings, including inpatient and specialist residential and community-based treatment settings, and prison services. It describes high-quality care in priority areas for improvement.

Quality standard Published November 2012

Needle and syringe programmes

Everything NICE has said on needle and syringe programmes for adults and young people who inject drugs in an interactive flowchart

NICE Pathway Published December 2011 Last updated March 2019

Drug misuse management in over 16s

Everything NICE has said on psychosocial interventions and opioid detoxification for drug misuse in an interactive flowchart

NICE Pathway Published January 2013 Last updated March 2019

Hepatitis B (chronic): diagnosis and management (CG165)

This guideline covers assessing and managing chronic hepatitis B in children, young people and adults. It aims to improve care for people with hepatitis B by specifying which tests and treatments to use for people of different ages and with different disease severities.

Clinical guideline Published June 2013 Last updated October 2017

Hepatitis B (chronic)

Everything NICE has said on diagnosing and managing chronic hepatitis B in children, young people and adults in an interactive flowchart

NICE Pathway Published June 2013 Last updated October 2017

Fertility problems: assessment and treatment (CG156)

This guideline covers diagnosing and treating fertility problems. It aims to reduce variation in practice and improve the way fertility problems are investigated and managed.

Clinical guideline Published February 2013 Last updated September 2017

Non-alcoholic fatty liver disease

Everything NICE has said on diagnosing and managing non-alcoholic fatty liver disease and advanced liver fibrosis in an interactive flowchart

NICE Pathway Published July 2016 Last updated June 2017

Cirrhosis

Everything NICE has said on assessing and managing suspected or confirmed cirrhosis in people over 16 in an interactive flowchart

NICE Pathway Published July 2016 Last updated November 2018

Child maltreatment: when to suspect maltreatment in under 18s (CG89)

This guideline covers the signs of possible child maltreatment in children and young people aged under 18 years. It aims to raise awareness and help health professionals who are not child protection specialists to identify the features of physical, sexual and emotional abuse, neglect and fabricated or induced illness.

Clinical guideline Published July 2009 Last updated October 2017

Immunisations for under 19s

Everything NICE has said on immunisation in under 19s in an interactive flowchart

NICE Pathway Published October 2011 Last updated October 2017

Obeticholic acid for treating primary biliary cholangitis (TA443)

NICE's technology appraisal guidance on sofosbuvir for treating chronic hepatitis C . The ERG noted that the way transition...

Technology appraisal guidance Published April 2017

Physical health of people in prisons (QS156)

This quality standard covers assessing, diagnosing and managing physical health problems of adults aged 18 years and older in prisons or young offender institutes. It describes high-quality care in priority areas for improvement.

Quality standard Published September 2017

Caesarean section (CG132)

This guideline covers when to offer caesarean section, procedural aspects of the operation and care after caesarean section. It aims to improve the consistency and quality of care for women who are considering a caesarean section or have had a caesarean section in the past and are now pregnant again.

Clinical guideline Published November 2011 Last updated April 2019

Immunisations: reducing differences in uptake in under 19s (PH21)

This guideline covers increasing immunisation uptake among children and young people aged under 19 years in groups and settings where immunisation coverage is low. It aims to improve access to immunisation services and increase timely immunisation of children and young people. It also aims to ensure babies born to mothers infected with hepatitis B are immunised.

Public health guideline Published September 2009 Last updated September 2017

Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)

Evidence-based recommendations on tenofovir disoproxil (Viread) for the treatment of chronic hepatitis B (HBV)

Technology appraisal guidance Published July 2009

Entecavir for the treatment of chronic hepatitis B (TA153)

Evidence-based recommendations on entecavir (Baraclude) for the treatment of chronic hepatitis B

Technology appraisal guidance Published August 2008

Telbivudine for the treatment of chronic hepatitis B (TA154)

Evidence-based recommendations on telbivudine (Sebivo) for the treatment of chronic hepatitis B

Technology appraisal guidance Published August 2008

Drug misuse in over 16s: psychosocial interventions (CG51)

This guideline covers using psychosocial interventions to treat adults and young people over 16 who have a problem with or are dependent on opioids, stimulants or cannabis. It aims to reduce illicit drug use and improve people’s physical and mental health, relationships and employment.

Clinical guideline Published July 2007

Physical health of people in prison (NG57)

This guideline covers assessing, diagnosing and managing physical health problems of people in prison. It aims to improve health and wellbeing in the prison population by promoting more coordinated care and more effective approaches to prescribing, dispensing and supervising medicines.

NICE guideline Published November 2016

Antenatal care for uncomplicated pregnancies (CG62)

This guideline covers the care that healthy women and their babies should be offered during pregnancy. It aims to ensure that pregnant women are offered regular check-ups, information and support.

Clinical guideline Published March 2008 Last updated February 2019

Lenvatinib for untreated advanced hepatocellular carcinoma (TA551)

Evidence-based recommendations on lenvatinib (Lenvima) for untreated advanced hepatocellular carcinoma (HCC) in adults

Technology appraisal guidance Published December 2018

Avatrombopag and lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing an elective procedure [ID1520]

In development [GID-TA10444] Expected publication date: 26 February 2020

Technology appraisal guidance In development

Health of people in the criminal justice system

Everything NICE has said on managing the physical and mental health of people in prison, and the mental health of people in the criminal justice system

NICE Pathway Published November 2016 Last updated September 2018

Donor milk banks: service operation (CG93)

This guideline covers how donor milk banks should recruit, screen and support women who donate breast milk. It also covers how milk banks should handle and process the breast milk they receive from donors. It aims to improve the safety of donor milk and operation of donor milk services.

Clinical guideline Published February 2010

Block scoping reports

NICE block scoping reports

Published May 2019

Static list

NICE technology appraisal guidance static list

Published January 2018

HIV testing: increasing uptake among people who may have undiagnosed HIV (NG60)

This guideline covers how to increase the uptake of HIV testing in primary and secondary care, specialist sexual health services and the community. It describes how to plan and deliver services that are tailored to the local prevalence of HIV, promote awareness of HIV testing and increase opportunities to offer testing to people who may have undiagnosed HIV.

NICE guideline Published December 2016

How can the uptake of hepatitis C treatment be improved? What factors influence whether or not specific groups at increased risk will begin and complete hepatitis C treatment?

uptake of hepatitis C treatment be improved? What factors influence whether or not specific groups at increased risk will begin and...

Research recommendation Published June 2015

Stent insertion for bleeding oesophageal varices (IPG392)

Evidence-based recommendations on stent (mesh tube) insertion for bleeding oesophageal varices

Interventional procedures guidance Published April 2011

Non-alcoholic fatty liver disease (NAFLD): assessment and management (NG49)

This guideline covers how to identify the adults, young people and children with non-alcoholic fatty liver disease (NAFLD) who have advanced liver fibrosis and are most at risk of further complications. It outlines the lifestyle changes and pharmacological treatments that can manage NAFLD and advanced liver fibrosis.

NICE guideline Published July 2016

Myeloma: diagnosis and management (NG35)

This guideline covers the diagnosing and managing of myeloma (including smouldering myeloma and primary plasma cell leukaemia) in people aged 16 and over. It aims to improve care for people with myeloma by promoting the most effective tests and treatments for myeloma and its complications.

NICE guideline Published February 2016 Last updated October 2018

Pre-exposure prophylaxis of HIV in adults at high risk: Truvada (emtricitabine/tenofovir disoproxil) (ESNM78)

Summary of the evidence on Truvada (emtricitabine/tenofovir disoproxil) for pre-exposure prophylaxis (PrEP) of HIV in adults at high risk

Evidence summary Published October 2016